tbuckley/cabot-search huggingface dataset:
MS-01 * DEVELOPMENT OF MALIGNANT PERIPHERAL NERVE TUMOR MODEL FOR EVALUATING A TUMOR TARGETED LIPOSOME-BASED THERAPY
Authors: M. Achutha, B. Slagle-Webb, E. Rizk, R. Payne, K. Harbaugh, J. Connor
Journal: Neuro-Oncology (2014)

In our previous studies we demonstrated the expression of IL-13Rα2 receptor in several malignant and benign peripheral nerve sheath tumors. In a subsequent study we investigated the specific binding of the IL-13 conjugated liposomal doxorubicin (IL13LIPDXR) to the MPNST cells and their cytotoxic property in the monolayer and spheroid model. To demonstrate the in vivo therapeutic efficacy, a sciatic nerve tumor model was developed in nude mice using STS26T, a MPNST cell line. The STS26T cell line was stably transfected with a luciferase expressing plasmid using a nanoliposome technology developed in our laboratory. These luciferase transfected cells were injected in the sciatic nerve in NIH III nude mice and allowed to grow for 2-4 weeks. To confirm the tumor formation intravital imaging spectroscopy (IVIS) and MR imaging were performed after injection of luciferin-D, a substrate for the luciferase. For our pathological studies, the mice were sacrificed and the tumor along with the nerve was dissected and paraffin embedded. The tumor was sectioned and the sections were subjected to immunohistochemistry (IHC) for the presence of IL-13Rα2 receptor protein, ki-67 a cell proliferation marker, heavy chain ferritin and S100 (myelin forming Schwann cells). Our experiment demonstrated the presence of IL-13R2 receptor, ki-67, H-ferritin and S100 at variable levels in the tumor. Experiments are in progress to develop an effective therapeutic strategy using IL-13 targeted liposomes.
Peanut Agglutinin Is a Novel Receptor for Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin (DC-SIGN).
Authors: Madhan Masilamani, Mohanapriya Kamalakannan, Lisa Chang, Galina Grishina, Hugh A. Sampson
Journal: Journal of Allergy and Clinical Immunology (2016)
Case 19-2009
Authors: Eunice L. Kwak, Theodore S. Hong, David L. Berger, David G. Forcione, Raul N. Uppot, Gregory Y. Lauwers
Journal: New England Journal of Medicine (2009)

A 63-year-old woman was seen for management of adenocarcinoma of the gastroesophageal junction. Two months earlier, dysphagia had developed. Endoscopic, radiologic, and pathological evaluation disclosed adenocarcinoma at the gastroesophageal junction, associated with Barrett's esophagus, and possible metastatic cancer in a regional lymph node. A treatment plan was established.
Abstract IA11: New insights into the microenvironment and metastasis
Authors: Zena Werb
Journal: Cancer Research (2011)

Abstract Both extrinsic and intrinsic mechanisms regulate the development of the aberrant tumor organ and regulate its progression. We have used genetic and in vivo imaging techniques to study the interaction between epithelial cancer cells and the tumor microenvironment during tumor progression. Transcriptional regulation of epithelial differentiation, cell-cell interaction and motility is a key intrinsic event in tumor progression. We have investigated GATA3, a master regulator for luminal differentiation, which is lost upon malignant conversion, and found that it allows the malignant tumor cells to disseminate throughout the body. The progressing tumor cells develop in an extrinsic microenvironment rich in inflammatory cells, growth factors, angiogenesis and activated stroma that promotes neoplastic risk. All of these components communicate with each other to contribute to the aberrant tumor organ. The tumor microenvironment regulates access to therapeutics and may alter expression of drug resistance genes. To explore the relationship between microenvironment and cancer cells in drug response, we treated mouse models of mammary carcinoma with doxorubicin. Primary cancer cells isolated from different tumor sizes had the same sensitivity in 2D and 3D cultures. Live imaging confirmed that individual cancer cells in early carcinoma stages were more sensitive to doxorubicin than in earlier or later stages. Imaging intact tumors during treatment with chemotherapy revealed marked differences in drug penetration and sensitivity of cancer cells in different tumor microenvironments. The inflammatory cells modulate the tumor ecology, altering vascular permeability and responses to chemotherapy. These experiments establish that chemosensitivity is determined by cooperation between cancer cell intrinsic and extrinsic factors. Supported by grants from the National Cancer Institute Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr IA11.
Acquired Afibrinogenemia in Pregnancy
Authors: William C. Moloney, William J. Egan, Arthur J. Gorman
Journal: New England Journal of Medicine (1949)

ONE of the most catastrophic events in obstetric practice is the occurrence of a fulminating hemorrhagic diathesis usually associated with toxemia of pregnancy and toxic separation of the placenta. Although uncommon, this usually fatal disorder has been encountered by most obstetricians of long experience.1 2 3 For many years it has been suspected that there was a common etiologic background for this hemorrhagic disorder and toxemia of pregnancy, and it has been postulated that the uterus and its contents were the source of a toxic factor.3 4 5 6 In spite of the various theories advanced no toxic substance has actually been identified in the . . .
Abstract 1581: IL-13 mediates signal transduction through IL-13 receptor α2 in pancreatic ductal adenocarcinoma: role of IL-13 pseudomonas exotoxin in pancreatic cancer therapy
Authors: Takeshi Shimamura, Toshio Fujisawa, Syed R. Husain, Bharat H. Joshi, Seitaro Watanabe, Shingo Kato, Noritoshi Kobayashi, Kensuke Kubota, Atsushi Nakajima, Raj K. Puri
Journal: Cancer Research (2010)

Abstract Purpose: Interleukin-13 receptor alpha 2 (IL-13Rα2) is a tumor antigen, which is overexpressed in certain human tumors. However, its expression and significance in pancreatic cancer and whether IL-13 can signal through IL-13Rα2 in cancer is not known. In addition, it is not known whether IL-13-PE can target pancreatic cancer for therapy. Experimental Design: The expression of IL-13Rα2 was assessed in pancreatic cancer samples by IHC; and in cell lines by flow cytometry and RT-PCR. The role of IL-13Rα2 was examined by IL-13 induced signaling in pancreatic cancer cell lines. IL-13Rα2 positive tumors were targeted by IL-13PE cytotoxin in vitro and in vivo in orthotopic murine model of human pancreatic cancer. Results: Seventy one percent pancreatic tumor samples overexpressed moderate- to high-density IL-13Rα2 compared to normal pancreatic samples. IL-13 induced TGF-β1 promoter activity in IL-13Rα2 positive tumor cells and in cells engineered to express IL-13Rα2 but not in IL-13Rα2-negative or RNAi knockdown cells. c-Jun and c-Fos of AP-1 family nuclear factors were activated by IL-13 only in IL-13Rα2-positive cells. In orthotopic mouse model, IL13-PE significantly decreased tumor growth when assessed by whole body imaging. In addition, IL13-PE prolonged the mean survival time of treated animals. Similar results were observed in mice xenografted orthotopically with a surgically resected human pancreatic tumor sample. Conclusions: These results indicate that IL-13Rα2 is a functional receptor as IL-13 mediates signaling in human pancreatic cancer cell lines. IL-13 causes TGF-β activation via AP-1 pathway, which may cause tumor induced immunosuppression in the host. In addition, IL13-PE cytotoxin may be an effective therapeutic agent for the treatment of pancreatic cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1581.
P3-12-04: Involved Anterior Margins after Breast Conserving Surgery: Is Re-Excision Required?
Authors: R Mullen, EJ Macaskill, A Khalil, E Elseedawy, DC Brown, AC Lee, C Purdie, L Jordan, AM Thompson
Journal: Cancer Research (2011)

Abstract Background: Complete tumour excision in breast conserving surgery (BCS) is critical for successful treatment; involved circumferential resection margins are associated with increased disease recurrence. However, the importance of an involved anterior margin is less clear. The purpose of this study was to audit an aggressive approach to involved anterior margins and hence assess whether anterior margin re-excision yields clinical benefit. Material and Methods: A retrospective case note and pathology review was performed for all patients who underwent BCS between 2006 and 2010 through a single cancer centre. An involved margin was defined as &amp;lt;1mm clearance of invasive or in situ breast cancer. Results: 1667 patients underwent BCS for invasive and/or in-situ disease, of whom 114 (6.8%) underwent re-excision, most commonly for mixed invasive and in-situ pathology. The annual re-excision rate rose significantly (p&amp;lt;0.001), with no change in whole tumour diameter, specimen weight or specimen volume. A total of 170 involved margins were identified: most commonly the anterior margin (59 margins, 30.6%) followed by the posterior (39 22.9%) or inferior (31, 18.3%) margin. Patients with anterior margin involvement were more likely to have grade 3 invasive disease (p=0.0323) but less likely to have residual disease found at re-excision (2/49 vs. 32/101 margins, p=0.0033); there were no differences when in-situ characteristics were compared. Conclusions: Re-excision of involved anterior margins rarely excises residual disease and may be unnecessary. Multidisciplinary teams should consider whether further therapy for an involved anterior margin is required on a patient by patient basis. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-12-04.
800 INCREASED EXPRESSION OF SUPPRESOR OF CYTOKINES 3 IN HCV NON RESPONDERS IS ASSOCIATED WITH IMPAIRED ANTI-HCV CELLULAR IMMUNE RESPONSE
Authors: D. Martinez, D. Simar, C. Palmer, B. Cameron, N. Nguyen, V. Aggarwal, A. Lloyd, A. Zekry
Journal: Journal of Hepatology (2012)
LA INYECCIÓN CON CIANOCRILATO GUIADA POR ULTRASONOGRAFÍA ENDOSCÓPICA ES UN MÉTODO PRECISO Y SEGURO EN EL TRATAMIENTO DE LAS VARICES GÁSTRICAS
Authors: R Romero, JC Subtil, F Junquera, E Brullet, M Betés, M Muñoz Navas, R Campo, F Pellicer, JM Herrerías
Journal: Endoscopy (2010)

Introducción: La inyección endoscópica con cianocrilato es el tratamiento estándard de las varices gástricas. Sin embargo su aplicación es difícil en caso de sangrado masivo, y se asocia a complicaciones severas tanto sistémicas (embolismos) como locales (hemorragia por úlceras). La inyección por ecoendoscopia puede ofrecer algunas ventajas: su aplicación es independiente de la visión endoscópica, monitoriza la oclusión completa de la variz y puede minimizar el riesgo de embolización al disminuir el volumen del cianocrilato inyectado.
SAT0363 Is there a before and after femoral neck fracture regarding quality of life? Corpo study: Comprehending osteoporosis real perception and overview:
Authors: L. Cunha-Miranda, E. Simões, S. Fernandes, N. Gonçalves, E. Leiria, L. Nogueira
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Femoral neck fracture is considered as one of the most severe consequence of osteoporosis (OP) due to its high mortality and morbidity, affecting patients' Health Related Quality of Life (HRQoL) physically, psychologically and socially<sup>1</sup>. <h3>Objectives</h3> To evaluate HRQoL and impact of femoral neck fracture in subjects lives in a high risk of fracture (HRF) population with and without self-reported OP. <h3>Methods</h3> HRQoL was assessed by SF12 scale and subjects perception on their HRQoL before and after the fracture. Cross-sectional survey including a convenience sample of HRF population selected randomly from nursing homes and long-term care facilities in Portugal. Inclusion criteria for subjects were age ≥50 years, history of a low impact femoral neck fracture on the 24 months prior, absence of cognitive limitations. Confidence intervals (CI) of 95% will be determined and calculations were performed assuming a 5% significance level. <h3>Results</h3> 419 HRF subjects were included, mean age 78.3±7.8, 70.4% female. From these 37.5% (n=157;CI: 32.9%&gt;42.2%) self-reported OP. Mean age for occurrence of a femoral neck fracture was 77.2±8.1, with no significant differences between subjects with and without self-reported OP (77.3±9.6 <i>vs.</i> 76.9±7.4; p=0.656). In a scale of 1 (worst possible) to 10 (better possible), significant differences were found for subjects' perception about their HRQoL before and after femoral neck fracture (7.0±2.4 <i>vs.</i> 4.2±2.3; p&lt;0.001) and between subjects with and without OP before and after the fracture (With OP: 7.9±1.7 <i>vs.</i> 4.9±2.2; p&lt;0.001; Without OP: 6.8±2.6 <i>vs.</i> 4.1±2.3; p&lt;0.001). In these groups, significant differences were observed before and after fracture (p=0.038). <h3>Conclusions</h3> Subject's perceptions of their HRQoL change after a femoral fracture. Lower HRQoL levels are reported by individuals after experiencing a femoral neck fracture. Fracture is a life altering event on people's lives diminishing their QoL. <h3>References</h3> Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 2000;11(5):460-6 <h3>Disclosure of Interest</h3> None Declared
AB0198 Plasma leucine-rich alpha-2 glycoprotein is a useful disease activity biomarker in rheumatoid arthritis
Authors: Y. J. Ha, J.-S. Song, E.-J. Kang, K. H. Lee, S. T. Choi
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Leucine-rich α2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats (LRRs). Though physiological functions of LRG have not been clarified yet, it has been reported that LRG could be a marker of granulocytic differentiation and its expression was up-regulated during neutrophil differentiation. LRG could show a significant increase in some inflammatory conditions, such as ulcerative colitis, in where serum LRG concentrations were well correlated with disease activity, and the expressions of LRG were increased in inflamed colonic tissues. However, the association between plasma LRG level and disease activity in RA patients remains obscure. <h3>Objectives</h3> This study aimed to investigate whether the plasma LRG level is elevated in patients with RA and its correlation with disease activity and other parameters. <h3>Methods</h3> Our study included 69 patients with RA and 48 age- and sex- matched healthy controls. Plasma samples were obtained from patients with RA during active and inactive disease status and from controls. We assessed the clinical characteristics and laboratory parameters including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and disease activity score 28 (DAS28). Plasma concentrations of tumor necrosis factor-α (TNF-α) and LRG were determined by enzyme-linked immunosorbent assay (ELISA). <h3>Results</h3> Plasma LRG concentrations were significantly elevated in RA patients compared with healthy control (30.8 ± 14.4 ng/mL vs 22.2 ± 6.1 ng/mL, <i>p</i>&lt;0.001). In patients with RA, plasma LRG levels were found to be correlated with DAS28, ESR, and CRP (<i>γ</i> = 0.671, <i>p</i>&lt; 0.001; <i>γ</i> = 0.612, <i>p</i>&lt; 0.001; and <i>γ</i> = 0.601, <i>p</i>&lt; 0.001, respectively), but not with plasma TNF-α levels. Plasma LRG levels in patients with an active disease status (DAS28 ≥2.6) were significantly higher than in patients with a remission status (DAS28&lt; 2.6) (36.45 ± 14.36 ng/mL vs 24.63 ± 8.81 ng/mL, <i>p</i>&lt;0.001). <h3>Image/graph</h3> <h3>Conclusions</h3> Patients with RA had higher plasma LRG levels than healthy subjects, and plasma LRG concentrations were well correlated with disease activity measures. Our findings suggest that plasma LRG could play a role in the inflammatory process independently of the TNF- α, and that it may be a novel biomarker for reflecting inflammatory activity in RA patients. <h3>References</h3> Serada S, Fujimoto M, Terabe F, Lijima H, Shinzaki S, Matsuzaki S, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 2012;18:2169-79 Shirai R, Hirano F, ohkura N, Ikeda K, Inoue S. Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun 2009;382:776-9 <h3>Disclosure of Interest</h3> None Declared
REDUCED GLOBAL LONGITUDINAL STRAIN IN APICAL (‘TAKOTSUBO’) STRESS CARDIOMYOPATHY: IMPLICATIONS FOR DIASTOLIC FILLING AND ASSESSMENT OF FILLING PRESSURES BY E/E’ RATIO
Authors: Aline Iskandar, Gerard Aurigemma, Samer Mowakeaa, Mohamed Ahmed, Timothy Fitzgibbons, Dennis Tighe
Journal: Journal of the American College of Cardiology (2015)
The Effect of Patients' Preferences on Racial Differences in Access to Renal Transplantation
Authors: John Z. Ayanian, Paul D. Cleary, Joel S. Weissman, Arnold M. Epstein
Journal: New England Journal of Medicine (1999)

In the United States, black patients undergo renal transplantation less often than white patients, but few studies have directly assessed the association between race and patients' preferences with respect to transplantation.
SAT0201 Induction therapy with short-term high dose intravenous cyclophosphamide followed by mycophenolate mofetil in patients with proliferative lupus nephritis
Authors: S. Arends, J.H. Berden, C. Grootscholten, R.H. Derksen, S.P. Berger, R.G. de Sévaux, A.E. Voskuyl, M. Bijl
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> For decades, high dose intravenous cyclophosphamide (ivCY) given for 24-30 months was regarded as standard therapy for proliferative lupus nephritis (LN), despite serious side effects.(1) <h3>Objectives</h3> To evaluate the effect of induction therapy with short-term high dose ivCY followed by mycophenolate mofetil (MMF) on renal function and mortality in patients with proliferative LN. <h3>Methods</h3> Between January 2003 and November 2006, 74 patients with biopsy-proven proliferative LN were included in the second Dutch LN Study. All patients were treated with ivCY (750 mg/m<sup>2</sup>, 6 pulses in 5 months) plus oral prednisone (OP; initially 1 mg/kg/day), followed by MMF (2000 mg/day) plus OP (10 mg/day) for 18 months, and then AZA (2 mg/kg/day) plus OP (10 mg/day) (CY/MMF group). Study endpoints included the occurrence of renal relapse, end-stage renal disease (ESRD), and mortality. Results were compared to 4-year follow-up data (median 4.0 years, range 0.1-4.5) of the first Dutch LN Study.(2) In this randomized controlled trial, patients with proliferative LN were treated with high dose ivCY (750 mg/m<sup>2</sup>, 13 pulses in 2 years) plus OP (initially 1 mg/kg/day) (CY group; n=50) or AZA (2 mg/kg/day) combined with intravenous methylprednisolone (3x3 pulses of 1000 mg) and OP (initially 20 mg/day) (AZA/MP group; n=37). After 2 years, all patients continued with AZA (2 mg/kg/day) plus OP (10 mg/day). <h3>Results</h3> After a median follow-up of 3.8 years (range 0.1-4.5), 4 patients (5%) of the CY/MMF group had a renal relapse, one patient (1%) reached ESRD, and 2 patients (3%) died. The occurrence of renal relapses in the CY/MMF group was comparable to the CY group (HR: 1.4, 95% CI: 0.3-7.5). Significantly less renal relapses occurred in the CY/MMF group compared to the AZA/MP group (HR: 0.2, 95% CI: 0.1-0.7). The occurrence of ESRD and mortality were comparable between treatment groups. <h3>Conclusions</h3> This open-label study shows that induction therapy with short-term (5 months) high dose ivCY followed by MMF is as effective as long-term (24 months) high dose ivCY in preventing renal relapses, ESRD, and mortality in patients with proliferative LN. <h3>References</h3> Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42. <h3>Disclosure of Interest</h3> None Declared
Abstract 1869: Genetic variants of DNA repair genes and lung cancer among nonsmokers: A pooled analysis in the International Lung Cancer Consortium
Authors: Yuan-Chin Amy Lee, Rayjean Hung, Paolo Boffetta, Paul Brennan, David Christiani, Chikako Kiyohara, Qing Lan, Adeline Seow, Vineis Paolo, Zuo-Feng Zhang
Journal: Cancer Research (2010)

Abstract Background Lung cancer among nonsmokers has been considered as a different disease from that among smokers. Involuntary smoking has been suggested to be a risk factor for lung cancer among nonsmokers with a modest effect. Few studies have examined the role of single nucleotide polymorphisms (SNPs) of the DNA repair genes and their potential interactions with involuntary smoking on the development of lung cancer among nonsmokers. Methods We evaluated the associations between SNPs of the DNA repair genes and lung cancer based on a pooled data of the International Lung Cancer Consortium. The individual-level epidemiological data and genotyping data on eight SNPs from six participating studies were pooled, including 845 nonsmoker cases and 4,262 nonsmoker controls. Logistic regression models with adjustment by age, sex, ethnicity, study, and ever involuntary smoking status were used to obtain odds ratios (OR) and 95% confidence intervals (CI). Results Among nonsmokers, the associations with the polymorphisms in OGG1 S326C and XPD D312N were observed among those with involuntary smoking (for OGG1 S326C: OR=1.61, 95% CI 1.18-2.20 for CG, OR=1.74, 0.99-3.06 for GG, compared to CC; for XPD D312N: OR=1.06, 0.76-1.47 for AG, OR=1.60, 1.06-2.42 for AA, compared to GG), but not for those without involuntary smoking (for OGG1 S326C: OR=0.78, 0.39-1.54 for CG, OR=0.88, 0.25-3.06 for GG, compared to CC; for XPD D312N: OR=1.13, 0.57-2.21 for AG, OR=0.81, 0.27-2.43 for AA, compared to GG). The association with XRCC3 T241M variant was detected for adenocarcinoma and non-small cell lung cancer among those without exposure to involuntary smoking (adenocarcinoma: OR=3.52, 1.21-10.20 for AA, OR=0.94, 0.38-2.38 for GA, compared to GG; and non-small cell lung cancer: OR=2.75, 1.05-7.21 for AA, OR=1.10, 0.51-2.38 for GA, compared to GG, respectively). Due to limited power, no apparent interaction between DNA repair SNPs and involuntary smoking was detected. Conclusion This is the first large-scale collaborative study on the relationship between DNA repair genetic variants and lung cancer among nonsmokers, accounting for involuntary smoking. Our results show that SNPs of the DNA repair genes may play an important role for lung cancer among nonsmokers, and the associations may vary by involuntary smoking status and histological subtype. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1869.
Detection of Human Immunodeficiency Virus Type 1 Provirus in Mononuclear Cells by in Situ Polymerase Chain Reaction
Authors: Omar Bagasra, Stephen P. Hauptman, Harold W. Lischner, Mark Sachs, Roger J. Pomerantz
Journal: New England Journal of Medicine (1992)

Studies of human immunodeficiency virus type 1 (HIV-1) infection have attempted to quantitate the viral load and correlate it with the degree of immune deficiency. In one study, only about 1 in 10,000 peripheral-blood mononuclear cells (PBMC) expressed HIV-1, but in other studies, at least 1 in 100 CD4-positive cells was infected and harbored the HIV-1 provirus.